In addition, TILs in combination with anti-PD-1 have shown promising anti-tumor responses in multiple cancer types, notably PDL1 negative metastatic cervical cancer [141], metastatic osteosarcoma [147], triple-negative breast cancer [148]. This evidence concerns the gene PDCD1 and cancer.